Comparative Immunogenicity of a Cytotoxic T Cell Epitope Delivered by Penetratin and TAT Cell Penetrating Peptides

por Brooks, Nicole, Esparon, Sandra, Pouniotis, Dodie, Pietersz, Geoffrey A.
Publicado 2015

Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope

por Brooks, Nicole, Hsu, Jennifer, Esparon, Sandra, Pouniotis, Dodie, Pietersz, Geoffrey A.
Publicado 2018

Dendritic cell immunotherapy: clinical outcomes

por Apostolopoulos, Vasso, Pietersz, Geoffrey A, Tsibanis, Anastasios, Tsikkinis, Annivas, Stojanovska, Lily, McKenzie, Ian FC, Vassilaros, Stamatis
Publicado 2014

Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]

por Apostolopoulos, Vasso, Pietersz, Geoffrey A, Tsibanis, Anastasios, Tsikkinis, Annivas, Drakaki, Heleni, Loveland, Bruce E, Piddlesden, Sara J, Plebanski, Magdalena, Pouniotis, Dodie S, Alexis, Michael N, McKenzie, Ian F, Vassilaros, Stamatis
Publicado 2006

Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2

por Wines, Bruce D., Trist, Halina M., Esparon, Sandra, Impey, Rachael E., Mackay, Graham A., Andrews, Robert K., Soares da Costa, Tatiana P., Pietersz, Geoffrey A., Baker, Ross I., Hogarth, P. Mark
Publicado 2021

Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases

por Yap, May Lin, McFadyen, James D, Wang, Xiaowei, Ziegler, Melanie, Chen, Yung-Chih, Willcox, Abbey, Nowell, Cameron J, Scott, Andrew M, Sloan, Erica K, Hogarth, P Mark, Pietersz, Geoffrey A, Peter, Karlheinz
Publicado 2019

Targeting Activated Platelets: A Unique and Potentially Universal Approach for Cancer Imaging

por Yap, May Lin, McFadyen, James D, Wang, Xiaowei, Zia, Nicholas A, Hohmann, Jan David, Ziegler, Melanie, Yao, Yu, Pham, Alan, Harris, Matthew, Donnelly, Paul S, Hogarth, P Mark, Pietersz, Geoffrey A, Lim, Bock, Peter, Karlheinz
Publicado 2017

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma

por Li, Ziduo, Ju, Xinsheng, Lee, Kenneth, Clarke, Candice, Hsu, Jennifer L., Abadir, Edward, Bryant, Christian E., Pears, Suzanne, Sunderland, Neroli, Heffernan, Scott, Hennessy, Annemarie, Lo, Tsun-Ho, Pietersz, Geoffrey A., Kupresanin, Fiona, Fromm, Phillip D., Silveira, Pablo A., Tsonis, Con, Cooper, Wendy A., Cunningham, Ilona, Brown, Christina, Clark, Georgina J., Hart, Derek N.J.
Publicado 2018